Last mentioned: Mar 10, 2026
Clinical Pivot
Major research institutions report progress on Phase 2 trials for GLP-1s in addiction treatment.
Addiction Anecdotes Surface
Widespread reports of patients on GLP-1s losing interest in alcohol and nicotine gain media attention.
Wegovy Approval
Semaglutide is approved specifically for chronic weight management, sparking global demand.
Ozempic Market Entry
FDA approves Ozempic (semaglutide), which later shows strong weight loss side effects.
First GLP-1 Approval
FDA approves Byetta (exenatide) for type 2 diabetes management.
Glucagon-like peptide-1 (GLP-1) receptor agonists, having already disrupted the diabetes and obesity markets, are now being investigated as a breakthrough treatment for addiction. Early clinical data suggests these medications can significantly reduce cravings for alcohol, nicotine, and opioids by modulating the brain's reward circuitry.
The rapid adoption of GLP-1 receptor agonists is catalyzing a shift toward 'companion nutrition' to address muscle loss and nutrient deficiencies. This evolution is driving a multi-billion dollar secondary market for specialized food products and integrated digital health monitoring tools.
This page surfaces every story mentioning GLP-1 Receptor Agonists across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where GLP-1 Receptor Agonists was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |